期刊文献+

助乳化剂对多囊脂质体影响的初步考察 被引量:3

Preliminary Study on Influence of Co-emulsifi ers on Multivesicular Liposomes
下载PDF
导出
摘要 以拓扑替康为模型药物,采用复乳法制备多囊脂质体,考察了分别以L-赖氨酸、聚乙烯醇和海藻酸钠为助乳化剂对脂质体粒径和包封率的影响。结果表明,三者均能作为助乳化剂得到多囊脂质体,但种类和用量对制品粒径和包封率均有显著影响。 Multivesicular liposomes (MVLs) loaded with topotecan were prepared by double emulsification The effects of L-lysine, polyvinyl alcohol and sodium alginate as co-emulsifier on the diameter and encapsulation efficiency of the multivesicular liposomes were investigated. The results showed that the MVLs could be obtained with the three compounds as co-emulsifier. The particle size and encapsulation efficiency were affected by the type and amount of co-emulsifier significantly.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2009年第10期758-760,765,共4页 Chinese Journal of Pharmaceuticals
基金 "重大新药创新"科技重大专项(2009ZX09310-003)
关键词 拓扑替康 多囊脂质体 助乳化剂 L-赖氨酸 聚乙烯醇 海藻酸钠 topotecan multivesicular liposome co-emulsifier L-lysine polyvinyl alcohol sodium alginate
  • 相关文献

参考文献7

  • 1Mantripragada S. Alipid based depot (DepoFoam technology) for sustained release drug delivery [J]. Prog LipidRes, 2002, 41 (5) : 392-406.
  • 2Toliyat T, Khorasanirad Z. Development of a DepoFoam technology for the sustained delivery of desferrioxamine mesylate [J]. DARU, 2003, 11 (3) : 88-94.
  • 3张秀国,雍政,张谦,赵水明.拓扑替康在临床应用的研究进展[J].中国新药与临床杂志,2003,22(11):691-696. 被引量:6
  • 4郝艳丽,邓英杰,陈妍,王秀敏.盐酸拓扑替康脂质体的制备及影响因素考察[J].中国药学杂志,2004,39(8):602-604. 被引量:7
  • 5Langston MV, Ramprasad MP, Kararli TT, et al. Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam) [J]. J Controlled Release, 2003, 89 (1) : 87-99.
  • 6陶昱斐,姚瑶,丁燕飞,陈若飞,肖灿.酪丝亮肽多囊脂质体的制备和体外释放研究[J].中国新药杂志,2008,17(3):228-232. 被引量:9
  • 7Roy R, Kim S. Multivesicular liposomes containing bleomycin for subcutaneous administration [J]. Cancer Chemother Pharmacol, 1991, 28 (2) : 105-108.

二级参考文献39

  • 1邱爽,陆融,赵岚,王松,周春雷,赵茜,李国力,高文远,姚智.三肽化合物酪丝亮肽抗肿瘤作用及对单核巨噬细胞激活作用机制[J].中国肿瘤生物治疗杂志,2005,12(2):129-133. 被引量:8
  • 2王莉,陆融,王犁明,赵琳,傅正,王松,李会强,杨海贤,章明放,金孟珏,姚智.酪丝亮肽对人肝癌BEL-7402裸鼠移植瘤的抑制作用[J].中国新药与临床杂志,2005,24(11):857-861. 被引量:6
  • 3WALL JG, BENEDETTI JK, O'RROUIKE MA, et al. Phase II trial to in hepatocellular carcinoma: a southwest oncology group study[J]. Invest New Drugs, 1997,15(3) :257-260.
  • 4BROWN ZA, BENEDETTI JK, WATTS DH, et al. Phase II trial to topotecan in hepatocellular carcinoma: a southwest oncology group study[J ]. Invest New Drugs, 1997,15(3):257-260.
  • 5KANCHERLA RR, NAIR JS, AHMED T, et al. Evaluation of topotecan and etoposide for Non-Hodgkin Lymphoma[ J ]. Cancer, 2001, 91(3) : 463-471.
  • 6MUDERSPACH LI, BLESSING JA, LEVENBACK C, et al. A phase Ⅱ study of Topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. Gynecol oncol, 2000, 81(2):213-215.
  • 7ARDIZZONI A, HANSEN H, DOMBERNOWSKY P, et al.Topotecan,a new active drug in the second-line treatment of small-cell lung cancer: a phase lI study in patients with refractory and sensitive diease[J]. J Clin Oncol,1997,15(5) :2090-2096.
  • 8SCHILLER JH, KIM KM, HUTSON P, et al. Phase Ⅱ study to topotecan in patients with extensive stage small cell carcinoma of the lung: an eastern cooperative oncolgy group trail[J]. J Clin Oncol, 1996,14 (8) : 2345-2352.
  • 9von PAWEL J ,SCHILLER JH, SHEPFERD FA, et al. Topotecan versus cyclophosphmide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J]. J Clin Oncol,1999,17(2) : 658-667.
  • 10HAINSWORTH JD, BORRIS HA, MORRISSEY LH, et al.Phase I trial of paclitaxel , earboplatin, and topoteean with or without filgrastim (granulocye-colony stimulating factor ) in the treatment of patients with advanced, refractory cancer[J ]. Cancer, 1999,85(5) : 1179-1185.

共引文献18

同被引文献28

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部